Why Syndax Is Skyrocketing 55% Today

This morning Syndax Pharmaceuticals (NASDAQ: SNDX) updated investors with initial data from a phase 1/2 trial evaluating its leukemia drug, and shares are soaring 55% at 12:05 pm EST on Tuesday.

Syndax is a clincial-stage healthcare company developing cancer drugs, including SNDX-5613, a therapy for the treatment of leukemia caused by specific genetic abnormalities, including rearrangements of the MLL gene (MLL-r) and NPM1 mutation.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source Fool.com